We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+43.68%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$1.35B
AUM Growth
+$397M
Cap. Flow
+$106M
Cap. Flow %
7.83%
Top 10 Hldgs %
60.29%
Holding
72
New
21
Increased
13
Reduced
7
Closed
23

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$84.3M
2
XNCR icon
Xencor
XNCR
+$62.7M
3
RNAM
Avidity Biosciences
RNAM
+$60.7M
4
AKUS
Akouos Inc
AKUS
+$44M
5
RCUS icon
Arcus Biosciences
RCUS
+$41M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$61.6M
2
FATE icon
Fate Therapeutics
FATE
+$51.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45M
4
KYNB
Kyntra Bio
KYNB
+$30.7M
5
IPHA
Innate Pharma
IPHA
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.14%
2 Miscellaneous 2.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
1
Xencor
XNCR
$1.94B
$147M 10.88%
4,547,072
+2,045,515
+82% +$62.7M
PRTA icon
2
Prothena Corp
PRTA
$479M
$98.6M 7.28%
9,426,640
– –
ORIC icon
3
Oric Pharmaceuticals
ORIC
$1.37B
$89.1M 6.58%
+2,642,218
New +$84.3M
MORF
4
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$76.8M 5.67%
2,837,973
+14,832
+0.5% +$278K
KURA icon
5
Kura Oncology
KURA
$1.13B
$75.1M 5.55%
4,608,529
+1,096,839
+31% +$15.8M
ASMB icon
6
Assembly Biosciences
ASMB
$694M
$73.5M 5.43%
262,816
+46,926
+22% +$10.9M
DRNA
7
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$69.1M 5.11%
2,721,993
-624,308
-19% -$13.4M
ANAB icon
8
AnaptysBio
ANAB
$1.67B
$68.7M 5.07%
3,075,014
+39,000
+1% +$713K
RNAM
9
DELISTED
Avidity Biosciences
RNAM
$59.5M 4.39%
+2,103,950
New +$60.7M
NGNE icon
10
Neurogene
NGNE
$732M
$58.7M 4.34%
176,834
-7,826
-4% -$2.04M
RCUS icon
11
Arcus Biosciences
RCUS
$3.72B
$44.8M 3.31%
1,810,000
+1,517,900
+520% +$41M
AKUS
12
DELISTED
Akouos Inc
AKUS
$44.5M 3.28%
+1,975,984
New +$44M
GERN icon
13
Geron
GERN
$970M
$41.9M 3.1%
+19,230,769
New +$28.7M
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$40.9M 3.02%
357,849
– –
RARE icon
15
Ultragenyx Pharmaceutical
RARE
$2.52B
$40.6M 3%
519,119
+147,911
+40% +$9.79M
SURF
16
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$33M 2.44%
5,033,861
+3,759,398
+295% +$13.6M
BCEL
17
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$31.7M 2.34%
1,489,185
+383,005
+35% +$6.77M
AMTI
18
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
$28.9M 2.14%
+1,150,000
New +$29M
CNST
19
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$25.2M 1.86%
+837,885
New +$30.2M
FATE icon
20
Fate Therapeutics
FATE
$291M
$21.3M 1.57%
619,855
-1,722,020
-74% -$51.3M
DNLI icon
21
Denali Therapeutics
DNLI
$3.84B
$17.7M 1.31%
733,561
+35,460
+5% +$834K
BMY.RT
22
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$17M 1.26%
4,748,300
+2,500,000
+111% +$9.02M
CYCN icon
23
Cyclerion Therapeutics
CYCN
$17.7M
$16.2M 1.2%
137,114
– –
FULC icon
24
Fulcrum Therapeutics
FULC
$294M
$16.1M 1.19%
+882,353
New +$13.9M
CRNX icon
25
Crinetics Pharmaceuticals
CRNX
$9B
$15.1M 1.11%
859,802
+509,802
+146% +$8.69M
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2020 Portfolio in Review

As of Q2 2020, EcoR1 Capital held 72 positions worth $1.35B, up 41% from $957M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $106M of net new capital in Q2 2020, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $51.3M trimmed.

  • EcoR1 Capital's largest Q2 2020 buy was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.
  • EcoR1 Capital added most to Xencor in Q2 2020, an estimated $62.7M increase.
  • EcoR1 Capital's biggest Q2 2020 reduction was Fate Therapeutics, cutting an estimated $51.3M.
  • EcoR1 Capital fully exited Arvinas in Q2 2020, selling an estimated $61.6M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.35B portfolio in Q2 2020.
  • EcoR1 Capital opened 21 new positions and closed 23 in Q2 2020.
  • EcoR1 Capital's portfolio value rose 41% quarter-over-quarter to $1.35B.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.